Japan is expected to lower the price of lecanemab, an Alzheimer's drug, following a health ministry panel's report citing its low cost-effectiveness. https://www.japantimes.co.jp/news/2025/07/10/japan/science-health/lecanemab-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #lecanemab #alzheimer039s #medicine #health #dementia